Companies AtriCure, Inc.
AtriCure CEO salary & total pay, FY2025: $9.2M
AtriCure (ATRC) CEO salary, fiscal 2025: Michael Carrel was paid a salary of $828,439 and $9,217,620 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me AtriCure, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Michael Carrel's complete compensation dossier
A PDF and a CSV sent to your email: Michael Carrel's pay in every fiscal year AtriCure, Inc. reported it, line by line, with Michael Carrel's equity grants and AtriCure, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $8,749,289FY2023
- $11,070,400FY2024
- $9,217,620FY2025
CEO total pay was $9,217,620 in fiscal 2025, down from $11,070,400 in fiscal 2024.
FY2025: salary $828,439 · bonus $0 · stock awards $7,203,478 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Carrel | $828,439 | $0 | $7,203,478 | $0 | $1,171,703 | $0 | $14,000 | $9,217,620 |
| President and Chief Executive Officer | ||||||||
| Douglas Seith | 572,220 | 0 | 2,697,173 | 0 | 659,390 | 0 | 21,200 | 3,949,983 |
| Chief Operating Officer | ||||||||
| Angela Wirick | 523,366 | 0 | 2,535,345 | 0 | 504,452 | 0 | 11,750 | 3,574,913 |
| Chief Financial Officer | ||||||||
| Salvatore Privitera | 447,765 | 0 | 1,888,003 | 0 | 364,218 | 0 | 14,000 | 2,713,986 |
| Chief Technical Officer | ||||||||
| Justin Noznesky | 452,112 | 0 | 1,618,264 | 0 | 367,754 | 0 | 11,750 | 2,449,880 |
| Chief Marketing and Strategy Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Carrel | $9,217,620 | $11,070,400 | $8,749,289 | ↓ −1,852,780 |
| Douglas Seith | 3,949,983 | 4,116,219 | 3,499,842 | ↓ −166,236 |
| Angela Wirick | 3,574,913 | 3,289,591 | 2,921,357 | ↑ +285,322 |
| Salvatore Privitera | 2,713,986 | — | 2,127,121 | — |
| Justin Noznesky | 2,449,880 | 2,273,373 | — | ↑ +176,507 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation philosophy is rooted in a pay for performance approach while also considering internal equity and fairness. This approach is designed to strongly link executive officer compensation to our performance. Executive incentive compensation is tied to measurable results intended to create long-term value for our stockholders.
| CEO STI target (% of salary) | 105% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Korn Ferry |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Carrel | RSU | 2025-03-01 | — | — | 50,335 | — | $1,949,978 |
| Justin Noznesky | RSU | 2025-03-01 | — | — | 19,359 | — | 749,968 |
| Salvatore Privitera | RSU | 2025-03-01 | — | — | 22,586 | — | 874,982 |
| Douglas Seith | RSU | 2025-03-01 | — | — | 32,266 | — | 1,249,985 |
| Justin Noznesky | PSU | 2025-03-01 | 9,679 | 19,359 | — | 38,718 | 865,934 |
| Salvatore Privitera | PSU | 2025-03-01 | 11,293 | 22,586 | — | 45,172 | 1,010,266 |
| Michael Carrel | PSU | 2025-03-01 | 58,724 | 117,449 | — | 234,898 | 5,253,500 |
| Douglas Seith | PSU | 2025-03-01 | 16,134 | 32,266 | — | 64,532 | 1,443,252 |
| Angela Wirick | PSU | 2025-03-01 | 15,166 | 30,330 | — | 60,660 | 1,356,661 |
| Angela Wirick | RSU | 2025-03-01 | — | — | 30,330 | — | 1,174,984 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Carrel | $1,949,978 | $5,253,500 | $0 | 72.9% |
| Justin Noznesky | 749,968 | 865,934 | 0 | 53.6% |
| Salvatore Privitera | 874,982 | 1,010,266 | 0 | 53.6% |
| Douglas Seith | 1,249,985 | 1,443,252 | 0 | 53.6% |
| Angela Wirick | 1,174,984 | 1,356,661 | 0 | 53.6% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Angela Wirick | RSU | — | 8,159 | — | $322,770 |
| Angela Wirick | PSU | — | 23,101 | — | 913,876 |
| Angela Wirick | RSU | — | 20,672 | — | 817,784 |
| Angela Wirick | PSU | — | 31,008 | — | 1,226,676 |
| Angela Wirick | RSU | — | 30,330 | — | 1,199,855 |
| Angela Wirick | PSU | — | 30,330 | — | 1,199,855 |
| Douglas Seith | RSU | — | 9,018 | — | 356,752 |
| Douglas Seith | PSU | — | 25,532 | — | 1,010,046 |
| Douglas Seith | RSU | — | 25,266 | — | 999,523 |
| Douglas Seith | PSU | — | 37,899 | — | 1,499,284 |
| Douglas Seith | RSU | — | 32,266 | — | 1,276,443 |
| Douglas Seith | PSU | — | 32,266 | — | 1,276,443 |
| Justin Noznesky | RSU | — | 5,368 | — | 212,358 |
| Justin Noznesky | PSU | — | 19,294 | — | 763,271 |
| Justin Noznesky | PSU | — | 15,198 | — | 601,233 |
| Justin Noznesky | RSU | — | 12,862 | — | 508,821 |
| Justin Noznesky | RSU | — | 19,359 | — | 765,842 |
| Justin Noznesky | PSU | — | 19,359 | — | 765,842 |
| Michael Carrel | RSU | — | 15,331 | — | 606,494 |
| Michael Carrel | PSU | — | 101,280 | — | 4,006,637 |
| Michael Carrel | RSU | — | 33,902 | — | 1,341,163 |
| Michael Carrel | PSU | — | 118,660 | — | 4,694,190 |
| Michael Carrel | RSU | — | 50,335 | — | 1,991,253 |
| Michael Carrel | PSU | — | 117,449 | — | 4,646,282 |
| Salvatore Privitera | PSU | — | 15,198 | — | 601,233 |
| Salvatore Privitera | RSU | — | 12,862 | — | 508,821 |
| Salvatore Privitera | RSU | — | 22,586 | — | 893,502 |
| Salvatore Privitera | PSU | — | 22,586 | — | 893,502 |
| Salvatore Privitera | RSU | — | 5,368 | — | 212,358 |
| Salvatore Privitera | PSU | — | 19,294 | — | 763,271 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert S. WhiteIndependent · Board Chair · Nominating and Corporate Governance · Strategy | $112,500 | $174,992 | $0 | $0 | $0 | $287,492 |
| Regina E. GrovesIndependent · Audit · Compliance, Quality & Risk (Chair) · Strategy | 82,500 | 174,992 | 0 | 0 | 0 | 257,492 |
| Sven A. WehrweinIndependent · Audit (Chair) · Compliance, Quality & Risk | 77,500 | 174,992 | 0 | 0 | 0 | 252,492 |
| Karen N. PrangeIndependent · Compensation (Chair) · Nominating and Corporate Governance | 70,000 | 174,992 | 0 | 0 | 0 | 244,992 |
| B. Kristine JohnsonIndependent · Compensation · Strategy (Chair) | 67,500 | 174,992 | 0 | 0 | 0 | 242,492 |
| Deborah H. TelmanIndependent · Compensation · Nominating and Corporate Governance (Chair) | 67,500 | 174,992 | 0 | 0 | 0 | 242,492 |
| Shlomo NachmanIndependent · Compliance, Quality & Risk · Strategy | 65,000 | 174,992 | 0 | 0 | 0 | 239,992 |
| Maggie YuenIndependent · Audit | 60,000 | 174,992 | 0 | 0 | 0 | 234,992 |
| Michael H. CarrelEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $175,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $602,500 |
| Equity awards (grant-date value) | $1,399,936 |
| All other compensation | $0 |
| Total cost of the board | $2,002,436 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names AtriCure as a peer
Companies that benchmark against ATRC
29 companies name ATRC as a compensation peer
- ACCURAY INCARAYFY2026
- Alphatec Holdings, Inc.ATECFY2025
- ANGIODYNAMICS INCANGOFY2026
- ARTIVION, INC.AORTFY2025
- AVANOS MEDICAL, INC.AVNSFY2025
- Axogen, Inc.AXGNFY2025
- CareDx, Inc.CDNAFY2025
- CONMED CorpCNMDFY2025
- Cytek Biosciences, Inc.CTKBFY2025
- ESTABLISHMENT LABS HOLDINGS INC.ESTAFY2025
- Inogen IncINGNFY2025
- Inspire Medical Systems, Inc.INSPFY2025
- iRhythm Holdings, Inc.IRTCFY2025
- KESTRA MEDICAL TECHNOLOGIES, LTD.KMTSFY2026
- MESA LABORATORIES INC /CO/MLABFY2026
- Mirion Technologies, Inc.MIRFY2025
- NEOGENOMICS INCNEOFY2025
- Organogenesis Holdings Inc.ORGOFY2025
- Orthofix Medical Inc.OFIXFY2025
- PROCEPT BioRobotics CorpPRCTFY2025
- RxSight, Inc.RXSTFY2025
- STAAR SURGICAL COSTAAFY2025
- SURMODICS INCSRDXFY2024
- TACTILE SYSTEMS TECHNOLOGY INCTCMDFY2025
- TANDEM DIABETES CARE INCTNDMFY2025
- TransMedics Group, Inc.TMDXFY2025
- TREACE MEDICAL CONCEPTS, INC.TMCIFY2025
- UFP TECHNOLOGIES INCUFPTFY2025
- Vericel CorpVCELFY2025
- ZimVie Inc.ZIMVFY2024
- ZYNEX INCZYXIFY2024
Each company listed discloses ATRC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATRC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies AtriCure, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Insulet Corporation | 2025 | Ashley McEvoy | $729,808 | $12,958,850 | $2,999,913 | $2,031,562 | $18,858,968 |
| 2 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 3 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 4 | Nevro Corp | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 5 | iRhythm Holdings, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 6 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 7 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | Axogen, Inc. | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 9 | LivaNova Plc | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 10 | Inspire Medical Systems, Inc. | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 11 | Staar Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 12 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 13 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 14 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 15 | Penumbra, Inc. | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
| — | Inari Medical, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| AtriCure, Inc. | not disclosed | PSU 50 · Restricted Stock 50 | No | Korn Ferry |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| Axogen, Inc. | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Glaukos Corporation | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Inari Medical, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inspire Medical Systems, Inc. | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| iRhythm Holdings, Inc. | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| LivaNova Plc | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Nevro Corp | 53.7% | RSU 50 · PSU 50 | No | Aon |
| Penumbra, Inc. | not disclosed | not disclosed | No | Compensia |
| Staar Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-18 | 40,373,427 | 1,745,379 | 62,342 | 95.71% | Passed |
| 2025 | 2025-05-19 | 32,367,751 | 8,655,946 | 120,985 | 78.67% | Passed |
| 2024 | 2024-05-13 | 35,640,238 | 6,475,860 | 98,239 | 84.43% | Passed |
| 2023 | 2023-05-25 | 33,710,016 | 6,620,611 | 63,645 | 83.45% | Passed |
| 2022 | 2022-05-25 | 39,728,864 | 1,415,119 | 58,190 | 96.42% | Passed |
| 2021 | 2021-05-20 | 39,361,546 | 1,793,104 | 17,033 | 95.6% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-18 | 95.71%a |
| 2025 | 2025-05-19 | 78.67%b |
| 2024 | 2024-05-13 | 84.43%c |
a. Approved under the standard stated in the filing — “abstention has the same effect as a vote "AGAINST".”.
b. Approved under the standard stated in the filing — “you "ABSTAIN", your abstention has the same effect as a vote "AGAINST".”.
c. Approved under the standard stated in the filing — “you "ABSTAIN", your abstention has the same effect as a vote "AGAINST".”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 64 : 1 |
|---|---|
| CEO total compensation | $9,217,620 |
| Median employee compensation | $144,309 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Vinayak Doraiswamy | Chief Scientific Officer | 2026-05-15 | D | 5,000 | $28 | $140,650 | Common | Form 4 ↗ |
| Robert S. White | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Sven A. Wehrwein | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Regina E. Groves | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Shlomo Nachman | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Maggie Yuen | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Deborah H. Telman | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Karen N. Prange | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| B. Kristine Johnson | Director | 2026-05-18 | A | 6,144 | 0 | 0 | Common | Form 4 ↗ |
| Karen N. Prange | Director | 2026-05-20 | D | 3,000 | 29 | 85,950 | Common | Form 4 ↗ |
| Salvatore Privitera | Chief Technical Officer | 2026-06-30 | A | 636 | 24 | 15,124 | Common | Form 4 ↗ |
| Karl S. Dahlquist | Chief Legal Officer | 2026-06-30 | A | 636 | 24 | 15,124 | Common | Form 4 ↗ |
| Vinayak Doraiswamy | Chief Scientific Officer | 2026-06-30 | A | 636 | 24 | 15,124 | Common | Form 4 ↗ |
| Michael H. Carrel | Director | 2026-06-30 | A | 636 | 24 | 15,124 | Common | Form 4 ↗ |
| Douglas Seith | Chief Operating Officer | 2026-06-30 | A | 527 | 24 | 12,532 | Common | Form 4 ↗ |
| Sven A. Wehrwein | Director | 2026-07-28 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sven A. Wehrwein | Director | 2026-07-28 | D | 25,000 | 38 | 946,000 | Common | Form 4 ↗ |
| Sven A. Wehrwein | Director | 2026-07-28 | A | 25,000 | 20 | 498,750 | Common | Form 4 ↗ |
| Vinayak Doraiswamy | Chief Scientific Officer | 2026-07-28 | D | 6,000 | 39 | 233,280 | Common | Form 4 ↗ |
| Justin Noznesky | Chief Mktg & Strategy Officer | 2026-07-29 | D | 6,182 | 39 | 239,862 | Common | Form 4 ↗ |
| Michael H. Carrel | Director | 2026-07-30 | D | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael H. Carrel | Director | 2026-07-30 | D | 700 | 0 | 0 | Common | Form 4 ↗ |
| Maggie Yuen | Director | 2026-08-05 | D | 3,500 | 38 | 134,470 | Common | Form 4 ↗ |
| Karen N. Prange | Director | 2026-08-05 | D | 3,564 | 39 | 138,283 | Common | Form 4 ↗ |
| Karl S. Dahlquist | Chief Legal Officer | 2026-08-24 | D | 9,370 | 49 | 458,099 | Common | Form 4 ↗ |
| Salvatore Privitera | Chief Technical Officer | 2026-09-02 | D | 7,763 | 53 | 407,558 | Common | Form 4 ↗ |
| Salvatore Privitera | Chief Technical Officer | 2026-09-08 | D | 3,657 | 55 | 201,135 | Common | Form 4 ↗ |
| Regina E. Groves | Director | 2026-09-11 | D | 5,313 | 54 | 288,071 | Common | Form 4 ↗ |
| Salvatore Privitera | Chief Technical Officer | 2026-09-23 | D | 4,519 | 60 | 271,140 | Common | Form 4 ↗ |
| Salvatore Privitera | Chief Technical Officer | 2026-11-04 | D | 8,404 | 65 | 546,260 | Common | Form 4 ↗ |
| B. Kristine Johnson | Director | 2026-11-06 | D | 2,452 | 58 | 143,393 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (86 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Carrel. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 9,217,620. View filing ↗
- Section 01, Douglas Seith. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 3,949,983. View filing ↗
- Section 01, Angela Wirick. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 3,574,913. View filing ↗
- Section 01, Salvatore Privitera. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 2,713,986. View filing ↗
- Section 01, Justin Noznesky. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 2,449,880. View filing ↗
- Section 03, Michael Carrel RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Justin Noznesky RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Salvatore Privitera RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Douglas Seith RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Justin Noznesky PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Salvatore Privitera PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Carrel PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Douglas Seith PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Angela Wirick PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Angela Wirick RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-06. Section “CEO Pay Ratio”. As printed: 64 : 1. View filing ↗
- Section 08, Robert S. White. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 287,492. View filing ↗
- Section 08, Regina E. Groves. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 257,492. View filing ↗
- Section 08, Sven A. Wehrwein. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 252,492. View filing ↗
- Section 08, Karen N. Prange. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 244,992. View filing ↗
- Section 08, B. Kristine Johnson. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 242,492. View filing ↗
- Section 08, Deborah H. Telman. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 242,492. View filing ↗
- Section 08, Shlomo Nachman. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 239,992. View filing ↗
- Section 08, Maggie Yuen. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 234,992. View filing ↗
- Section 08, Michael H. Carrel. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Vinayak Doraiswamy 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert S. White 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sven A. Wehrwein 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Regina E. Groves 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shlomo Nachman 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maggie Yuen 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah H. Telman 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen N. Prange 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, B. Kristine Johnson 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen N. Prange 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Salvatore Privitera 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karl S. Dahlquist 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vinayak Doraiswamy 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael H. Carrel 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Douglas Seith 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sven A. Wehrwein 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sven A. Wehrwein 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sven A. Wehrwein 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vinayak Doraiswamy 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Noznesky 2026-07-29. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael H. Carrel 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael H. Carrel 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maggie Yuen 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen N. Prange 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karl S. Dahlquist 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Salvatore Privitera 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Salvatore Privitera 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Regina E. Groves 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Salvatore Privitera 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Salvatore Privitera 2026-11-04. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, B. Kristine Johnson 2026-11-06. Form 4, filed 2026-11-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-19. Item 5.07 · say-on-pay result. As reported: 95.71% (votes for as printed: 40,373,427). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-20. Item 5.07 · say-on-pay result. As reported: 78.67% (votes for as printed: 32,367,751). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-14. Item 5.07 · say-on-pay result. As reported: 84.43% (votes for as printed: 35,640,238). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 602,500 + equity 1,399,936 + all other 0 = 2,002,436, summed across the director compensation table rows.
- Insulet Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Glaukos Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. View filing ↗
- Nevro Corp, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro Corp's own proxy. As printed: 11,453,548. View filing ↗
- iRhythm Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Holdings, Inc.'s own proxy. As printed: 11,003,163. View filing ↗
- Alphatec Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
- AtriCure, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- Axogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Axogen, Inc.'s own proxy. As printed: 9,047,454. View filing ↗
- LivaNova Plc, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova Plc's own proxy. As printed: 8,047,217. View filing ↗
- Inspire Medical Systems, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. View filing ↗
- Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
- Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
- Tandem Diabetes Care, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. View filing ↗
- Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
- Penumbra, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. View filing ↗
- Section 10a, Tandem Diabetes Care, Inc. reciprocity. DEF 14A. Tandem Diabetes Care, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, iRhythm Holdings, Inc. reciprocity. DEF 14A. iRhythm Holdings, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, STAAR Surgical Company reciprocity. DEF 14A. STAAR Surgical Company names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Tactile Systems Technology, Inc. reciprocity. DEF 14A. Tactile Systems Technology, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Inspire Medical Systems, Inc. reciprocity. DEF 14A. Inspire Medical Systems, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Axogen, Inc. reciprocity. DEF 14A. Axogen, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Artivion, Inc. reciprocity. DEF 14A. Artivion, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Alphatec Holdings, Inc. reciprocity. DEF 14A. Alphatec Holdings, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Nevro Corp reciprocity. DEF 14A. Nevro Corp names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗